Navigation Links
Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
Date:9/12/2013

n shares were traded, which is below the daily average volume of 1.32 million. InterMune Inc.'s shares have rallied 53.59% in the last three months, outperforming the S&P 500 which has gained 3.87% during the same period. Moreover, InterMune Inc's stock is trading above its 50-day and 200-day moving averages of $13.74 and $10.58, respectively. The free report on ITMN can be downloaded by signing up now at:

http://www.AAAResearchReports.com/ITMN091213.pdf

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information pr
'/>"/>

SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
2. Todays Technical View: AstraZeneca, GlaxoSmithKline, Keryx Biopharma, and Raptor Pharma
3. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
4. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
5. Invitation to Register: Annual Defense Threat Reduction Agency Basic Research Technical Review
6. BC Technical Acquires MEDX
7. Call for Papers for Pittcon 2014 Technical Program
8. Technical Workshops at OrthoTec 2013 Focus on Risk Management Throughout Medical Device Lifecycle and Robust Material Selection Process Development
9. Formedix to Host Webinar: Discover Define-XML - Practical Uses Today and a Technical Deep Dive on March 14, 2013
10. 20% Off Your Entire Order of Scientific, Technical, Medical (STM) Book Titles Until the End of March at Chemical Publishing Company
11. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... highlights for the three and six month ... experienced a strong second quarter with the ... therapy treatment in,refractory head and neck cancer ...
... DIEGO, July 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... quarter 2008,financial results after the NASDAQ Global Market ... Jack Lief, Arena,s President and Chief,Executive Officer, and ... Financial Officer, will host a conference call at ...
... Abt Associates has been,ranked 19th in the Marketing News ... Research firms. The listing is based on 2007 revenue ... for,calendar 2007 was $55.1 million. Total company revenues for ... Abt Associates market research activities are carried out ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 9Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 10Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 11Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 12Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 13Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 14Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 15Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 16Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 17Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 18Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 19Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 20Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 21Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 22Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 23Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 24Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 25Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 26Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 27Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 28Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 29Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 30Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 31Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 32Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 33Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 2Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 3Abt Associates Ranked One of Top 20 U.S. Market Research Firms 2
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... Medical Branch at Galveston are the first to ... cervical cancer should begin colorectal cancer screening earlier ... finding a high incidence of secondary colorectal cancers ... new recommendations that the younger women in this ... after their initial cervical cancer diagnosis instead of ...
(Date:4/17/2014)... View of Domestication," a special feature of The ... ( PNAS ) published April 29, raises a ... deep history that most of us take for granted. ... in many spots around the globe shifted from hunting ... and plants. , It seems so straightforward and yet ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... one of the most important prerequisites for a positive self ... rather than the exception that children and young people are ... or subject to bullying are particularly critical of their appearance ... long period. This is revealed in a new thesis in ...
... Prevention (CDC) today released new infection control recommendations ... (KPC)-Producing Organisms, one of the most ... that infections with these highly resistant bacteria are ... In Guidance for Control of Infections with Carbapenem-Resistant ...
... the media. A new study by Dr. Yaniv Levyatan ... of Israel,s National Security College, describes how our side ... "Information warfare" plays a crucial role in ... conventional weapons. Therefore, the information warfare against terrorist organizations ...
Cached Biology News:Children who are dissatisfied with their appearance often have problems with their peer group 2Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms 2Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: